Next Article in Journal
Rectal Cancer: 20% Risk Reduction Thanks to Dietary Fibre Intake. Systematic Review and Meta-Analysis
Previous Article in Journal
Consumer Perceptions and Acceptability of Traditional Dishes Prepared with Provitamin A-Biofortified Maize and Sweet Potato
Previous Article in Special Issue
Precision Nutrition and the Microbiome Part II: Potential Opportunities and Pathways to Commercialisation
Article Menu

Export Article

Version is current.

Open AccessReview

The Potential Use of Metabolic Cofactors in Treatment of NAFLD

1
Science for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden
2
Centre for Host–Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London SE1 9RT, UK
3
School of Medicine, Koç University, Istanbul 34450, Turkey
4
Department of Gastroenterology and Hepatology, School of Medicine, Koç University, Istanbul 34450, Turkey
5
Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital Gothenburg, 41345 Gothenburg, Sweden
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1578; https://doi.org/10.3390/nu11071578
Received: 1 May 2019 / Revised: 4 July 2019 / Accepted: 5 July 2019 / Published: 12 July 2019
(This article belongs to the Special Issue Precision Nutrition and Metabolic Disease)
  |  
PDF [628 KB, uploaded 12 July 2019]
  |  

Abstract

Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Even though there is a multi-disciplinary effort for development of a treatment strategy for NAFLD, there is not an approved effective medication available. Single or combined metabolic cofactors can be supplemented to boost the metabolic processes altered in NAFLD. Here, we review the dosage and usage of metabolic cofactors including l-carnitine, Nicotinamide riboside (NR), l-serine, and N-acetyl-l-cysteine (NAC) in human clinical studies to improve the altered biological functions associated with different human diseases. We also discuss the potential use of these substances in treatment of NAFLD and other metabolic diseases including neurodegenerative and cardiovascular diseases of which pathogenesis is linked to mitochondrial dysfunction. View Full-Text
Keywords: NAFLD; metabolic cofactors; l-carnitine; nicotinamide riboside; l-serine; N-acetyl-l-cysteine NAFLD; metabolic cofactors; l-carnitine; nicotinamide riboside; l-serine; N-acetyl-l-cysteine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Mardinoglu, A.; Ural, D.; Zeybel, M.; Yuksel, H.H.; Uhlén, M.; Borén, J. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients 2019, 11, 1578.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top